Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SZC for Potassium Variability in Hemodialysis
NCT06736184Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 4, randomised, open-label trial of sodium zirconium cyclosilicate in hyperkalemia (2 arms), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: QT dispersion at 12 months. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT06736184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06736184.